Immutep Limited (ASX: IMM) operates as a biotechnology company. Immutep offers its services worldwide.
The company has recently stated the details about its participation in Oppenheimer’s 29th Annual Healthcare Conference. The CEO of the company Mr Marc Voigt is slated to present a corporate overview and a business update on the operations of the company.
The conference is slated to occur as on 19 March 2019, from 9:10 AM to 9:40 AM E.S.T at the Westin New York Grand Central, New York, USA. The conference shall presented by Mr Marc Voigt.
The company will be facilitating the viewing of the conference, for which it will be sharing a link of the webcast on the company’s website.
During the first half of financial year 2019, company reported strong progress with its clinical development program and its partnerships. Encouraging data was reported from its lead immunotherapy product candidate efti, with data from its phase I TACTI-mel clinical trial presented at leading industry conferences. In July 2018, Immutep’s investigational new drug (IND) application for efti was accepted by the US Food and Drug Administration (FDA). This marks the achievement of a significant operational milestone for the Company as it enables the clinical evaluation of efti in US clinical trial sites for TACTI-002. Also, during the half year, two new European patents were granted for Immutep. These patents protect efti in combination with a PD-1 or PD-L1 inhibitor and in combination with therapeutic antibodies for treating cancer.
The company’s financial position was strengthened in December 2018 with the U.S. capital raise of US$5.2 million. This was the second capital raise event by using American Depository Shares (ADS) since listing on NASDAQ in 2012. Strategically, this has provided important financial headroom to fund existing clinical development programs and brought U.S. specialist healthcare institutional investors onto the share register. In September and October 2018, the company has received US$ 1.05 million from the exercising of ADS warrants which were issued in July 2017. In August 2018, Immutep received a €1.22 million cash rebate from the French Government for the research and development activities conducted in Europe during the calendar year 2017. At 31 December 2018, the consolidated entity had total funds of A$26.0 million comprising cash in hand at the bank of A$7.6 million and short-term deposits of A$18.4 million.
On the price performance front, the stock has posted the YTD return of 25%. The company also posted returns of -5.41%, 6.06% & 16.67% over the past six months, three & one-month period respectively. At the time of writing (07 March 2019, AEST 01:40 PM), the stock of the company is trading at a price of $0.035, performing flat during the day’s trade with a market capitalisation of ~$ 118.43 Mn. The stock opened the day at $ 0.034, reached the day’s high of $ 0.035 and touched the day’s low of $ 0.034, with an average daily volume of ~ 2,570,820. It had a 52-week high price of $ 0.056 and a 52 weeks low price of $ 0.022, with an average volume of, 1,777,424 approximately.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.